US4765974A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Preparation for percutaneous administration
Assignee: Nitto Denko Corp
•
Filing: 1987-05-13
•
Granted: 1988-08-23
•
Expires: 2007-05-13
Abstract
Abstract A clonidine preparation for percutaneous administration comprising a support having provided thereon an active ingredient-containing layer is disclosed. The active ingredient-containing layer contains an acrylic polymer having a glass transition temperature of from -70° C. to -10° C. and pressure-sensitive adhesion at room temperature as a base, at least one of clonidine and clonidine hydrochloride as an active ingredient, and a decomposition inhibitor. The active ingredient can be stably maintained within the preparation without being decomposed, and, therefore, can be effectively released over a prolonged period of time.
Inventors
- 👤 Shoichi Tokuda
- 👤 Yuusuke Ito
- 👤 Saburo Otsuka
- 👤 Takashi Kinoshita
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 14:45
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K47/00; A61K47/30; A61K47/32; A61K9/00; A61K9/0012; A61K9/0014
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
142 words
A clonidine preparation for percutaneous administration comprising a support having provided thereon a layer containing an acrylic polymer having a glass transition temperature of from -70° C. to -10° C. and pressure-sensitive adhesion at room temperature as a base, at least one of clonidine and clonidine hydrochloride as an active ingredient, and at least one decomposition inhibitor which inhibits the decomposition of clonidine or clonidine hydrochloride, thereby maintaining the clonidine or clonidine hydrochloride in a stable state within the preparation for a long period of time, wherein said acrylic polymer is a copolymer comprising an alkyl (meth)acrylate having 4 or more carbon atoms in the alkyl moiety thereof, and a monomer copolymerizable with said alkyl (meth)acrylate and said decomposition inhibitor is selected from the group consisting of at least one of citric acid and succinic acid, and sodium and potassium salts thereof.
Claim 2
Dependent Claim
142 words
A clonidine preparation for percutaneous administration comprising a support having provided thereon a layer containing an acrylic polymer having a glass transition temperature of from -70° C. to -10° C. and pressure-sensitive adhesion at room temperature as a base, at least one of clonidine and clonidine hydrochloride as an active ingredient, and at least one decomposition inhibitor which inhibits the decomposition of clonidine or clonidine hydrochloride, thereby maintaining the clonidine or clonidine hydrochloride in a stable state within the preparation for a long period of time, wherein said acrylic polymer is a copolymer comprising an alkyl (meth)acrylate having 4 or more carbon atoms in the alkyl moiety thereof, and a monomer copolymerizable with said alkyl (meth)acrylate and said decomposition inhibitor is selected from the group consisting of at least one of citric acid and succinic acid, and sodium and potassium salts thereof.
Claim 3
Dependent Claim
22 words
A clonidine preparation for percutaneous administration as in claim 1, wherein said copolymer comprises from 50 to 99% by weight alkyl acrylate.
Claim 4
Dependent Claim
42 words
A clonidine preparation for percutaneous administration as in claim 1, wherein said at least one of clonidine and clonidine hydrochloride is or are present in an amount of from 1 to 25% by weight based on the weight of the acrylic polymer.
Claim 5
Dependent Claim
47 words
A clonidine preparation for percutaneous administration as in claim 1, wherein at least one of said citric acid and succinic acid, and sodium and potassium salts thereof is present in an amount of from 0.1 to 5% by weight based on the weight of the acrylic polymer.
Claim 6
Dependent Claim
47 words
A clonidine preparation for percutaneous administration as in claim 4, wherein at least one of said citric acid and succinic acid, and sodium and potassium salts thereof is present in an amount of from 1 to 4% by weight based on the weight of the acrylic polymer.
Claim 7
Dependent Claim
22 words
A clonidine preparation for percutaneous administration as in claim 1, wherein said layer has a thickness of from 5 to 500 μm.
Claim 8
Dependent Claim
22 words
A clonidine preparation for percutaneous administration as in claim 6, wherein said layer has a thickness of from 10 to 100 μm.
Claim 9
Dependent Claim
22 words
A clonidine preparation for percutaneous administration as in claim 1, wherein said support has a thickness of from 6 to 300 μm.
Claim 10
Dependent Claim
22 words
A clonidine preparation for percutaneous administration as in claim 1, wherein said support has a thickness of from 10 to 100 μm.
Claim 11
Dependent Claim
26 words
A clonidine preparation for percutaneous administration as in claim 1, wherein said at least one decomposition inhibitor is citric acid, succinic acid or a mixture thereof.
Claim 12
Dependent Claim
24 words
A clonidine preparation for percutaneous administration as in claim 3, wherein clonidine is present and the at least one decomposition inhibitor is succinic acid.
References Cited (Backward Citations)
US3896789A
Cited
GB1577259A
Cited
US4409206A
Cited
JPS56100715A
Cited
US4552751A
Cited
US4390520A
Cited
US4420470A
Cited
JPS57183714A
Cited
JPS5976019A
Cited
JPS59164714A
Cited
JPS6028917A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-23 | 1992-02-22 | 1992-08-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-23 | 1996-02-22 | 1996-08-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-23 | 2000-02-22 | 2000-08-23 | $7700.00 | Window Closed / Lapsed |